Page last updated: 2024-12-05

tripelennamine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Tripelennamine hydrochloride is an antihistamine that blocks the effects of histamine, a chemical that is released by the body in response to an allergic reaction. It is used to treat allergy symptoms such as sneezing, runny nose, itchy eyes, and hives. Tripelennamine hydrochloride is a white, crystalline powder that is soluble in water. It is typically administered orally, but it is also available as a topical cream and eye drops. Tripelennamine hydrochloride is a relatively safe drug, but it can cause side effects such as drowsiness, dizziness, and dry mouth. It is important to note that tripelennamine hydrochloride can interact with other medications, so it is important to talk to your doctor before taking it.'

Cross-References

ID SourceID
PubMed CID9066
CHEMBL ID1200446
SCHEMBL ID98916
MeSH IDM0329564

Synonyms (120)

Synonym
MLS001148406 ,
dehistin
MLS000069522 ,
n-[benzyl-n-(dimethylamino)ethyl] .alpha.-aminopyridine hydrochloride
tripelannamine hydrochloride
antiallergicum medivet
n,n-dimethyl-n'-(2-pyridyl)-n'-benzylethylenediamine hydrochloride
154-69-8
ahistamin
1, n,n-dimethyl-n'-(phenylmethyl)-n'-2-pyridinyl-, monohydrochloride
piristin
tripelennamine hydrochloride
stanzamine
pyrinamine
wln: t6nj bn1r & 2n1 & 1 & gh
tripelennamine monohydrochloride
nsc409943
2-[benzyl[2-(dimethylamino)ethyl]amino]pyridine hydrochloride
n(sup 1)-.alpha.-pyridyl-n(sup 1)-benzyl-n,n-dimethyl ethylenediamine monohydrochloride
nsc-409943
n-benzyl-n-.alpha.-pyridyl-n',n'-dimethyl-aethylendiamin-hydrochlorid
ethylenediamine,n'-dimethyl-n-(2-pyridyl)-, hydrochloride
n-benzyl-n',n'-dimethyl-n-2-pyridyl-ethylenediamine hydrochloride
pyribenzamine hydrochloride
pyristine (pristina) hydrochloride
pyrabenzamine
dehistin monohydrochloride
pyribenzamine monohydrochloride
tripelenamine hydrochloride
tripelennamine hcl
nsc 409943
re-covr injectable (veterinary)
n(sup 1)-alpha-pyridyl-n(sup 1)-benzyl-n,n-dimethyl ethylenediamine monohydrochloride
pyridine, 2-(benzyl(2-(dimethylamino)ethyl)amino)-, hydrochloride
2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine monohydrochloride
pbz-sr
tri-tumine
n-benzyl-n-alpha-pyridyl-n',n'-dimethyl-aethylendiamin-hydrochlorid [german]
nih 10186
recovr
1,2-ethanediamine, n,n-dimethyl-n'-(phenylmethyl)-n'-2-pyridinyl-, monohydrochloride
n-benzyl-n-dimethylaminoethyl alpha-aminopyridine hydrochloride
pyridine, 2-(benzyl(2-(dimethylamino)ethyl)amino)-, monohydrochloride
ethylenediamine, n-benzyl-n',n'-dimethyl-n-(2-pyridyl)-, hydrochloride
2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine hydrochloride
ccris 1969
einecs 205-833-5
MLS000758254
cpd000058623 ,
tripelennamine hydrochloride (usp)
pbz-sr (tn)
D02091
1,2-ethanediamine, n,n-dimethyl-n'-(phenylmethyl)-n'-2-pyridinyl-, hydrochloride
smr000058623
n-benzyl-n',n'-dimethyl-n-pyridin-2-ylethane-1,2-diamine hydrochloride
n'-benzyl-n,n-dimethyl-n'-pyridin-2-ylethane-1,2-diamine hydrochloride
CHEMBL1200446
tripelennamine chloride
A809564
n'-benzyl-n,n-dimethyl-n'-(2-pyridyl)ethane-1,2-diamine hydrochloride;tripelennamine hydrochloride
sr-01000003013
SR-01000003013-7
unii-fwv8gj56zn
fwv8gj56zn ,
tripelennamine hydrochloride [usp]
n-benzyl-n-alpha-pyridyl-n',n'-dimethyl-aethylendiamin-hydrochlorid
22306-05-4
1,2-ethanediamine, n1,n1-dimethyl-n2-(phenylmethyl)-n2-2-pyridinyl-, hydrochloride (1:?)
MLS001423999
CCG-100816
tripelennamine (hydrochloride)
CS-1395
FT-0631854
2-[benzyl[2-(dimethylamino)ethyl]amino]pyridine monohydrochloride
tripelennamine hydrochloride [usp monograph]
tripelennamine hydrochloride [usp-rs]
tripelennamine hydrochloride [mi]
tripelennamine hydrochloride [orange book]
tripelennamine hydrochloride [vandf]
tripelennamine hydrochloride [who-dd]
tripelennamine hydrochloride [green book]
tripelennamine hydrochloride [mart.]
AKOS015913800
S3146
HY-17428
SCHEMBL98916
NC00066
2-(benzyl(2-(dimethylamino)ethyl)amino)-pyridinhydrochloride
W-108029
n1-benzyl-n2,n2-dimethyl-n1-(pyridin-2-yl)ethane-1,2-diamine hydrochloride
OPERA_ID_1597
DTXSID6026248 ,
mfcd00012815
pyribenzamine hcl
tripelennamine hydrochloride, united states pharmacopeia (usp) reference standard
AS-59347
n-benzyl-n-[2-(dimethylamino)ethyl]pyridin-2-amine hydrochloride
tripelennamine hydrochloride, analytical standard
n~1~-benzyl-n~2~,n~2~-dimethyl-n~1~-(2-pyridinyl)-1,2-ethanediamine hydrochloride
154-69-8 (hcl)
SR-01000003013-6
SW197446-3
FSSICIQKZGUEAE-UHFFFAOYSA-N
n,n-dimethyl-n-(phenylmethyl)-n-pyridin-2-ylethane-1,2-diamine hydrochloride
Z1546621741
tripelennamine hydrochloride 100 microg/ml in acetonitrile
2-(benzyl(2-(dimethylamino)ethyl)amino)-pyridine hydrochloride
n'-benzyl-n,n-dimethyl-n'-pyridin-2-ylethane-1,2-diamine;hydrochloride
D70467
Q27278242
1,2-ethanediamine,n1,n1-dimethyl-n2-(phenylmethyl)-n2-2-pyridinyl-,hydrochloride
EN300-123046
tripelennaminehydrochloride
2-(benzyl(2-(dimethylamino)ethyl)amino)pyridinemonohydrochloride
tripelennamine hydrochloride (usp monograph)
dtxcid406248
tripelennamine hydrochloride (usp-rs)
re-covr
tripelennamine hydrochloride injection
tripelennamine hydrochloride (mart.)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency50.11870.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
GLS proteinHomo sapiens (human)Potency15.84890.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency6.51310.000811.382244.6684AID686978
chromobox protein homolog 1Homo sapiens (human)Potency63.09570.006026.168889.1251AID540317
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID1454
survival motor neuron protein isoform dHomo sapiens (human)Potency0.63100.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency0.02530.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's7 (77.78)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.98 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index80.89 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (52.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]